Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.

Diabetes in family does not increase risk of CVD

27 Sep 2020

A family history of diabetes appears to be unrelated to the risk of incident cardiovascular disease (CVD), reports a recent study. Parental myocardial infarction (MI) or stroke, however, may be linked to CVD onset.

Researchers retrieved data from four prospective German cohorts: The EPIC-Postdam (n=26,054), CARLA (n=1,079), SHIP (n=3,974), and KORA (n=15,777) studies. Multivariable-adjusted Cox regression analyses were performed to determine correlations between familial history and CVD risk. A meta-analysis was performed to obtain combined risk estimates.

Across all four cohorts, researchers found no clear link between diabetes history in any first-degree relative and the risk of CVD (combined hazard ratio [HR], 1.04, 95 percent confidence interval [CI], 0.90–1.21).

Both maternal (combined HR, 1.05, 95 percent confidence interval CI, 0.93–1.18) and paternal (combined HR, 0.96, 95 percent CI, 0.81–1.14) histories did not Increase CVD risk, and neither did a general parental history of diabetes (combined HR, 0.99, 95 percent CI, 0.88–1.10). The same was true for a sibling history of diabetes (combined HR, 1.25, 95 percent CI, 0.97–1.61).

Disaggregating CVD into its components of MI and stroke did not meaningfully change the principal results in general. However, there was a significant signal detected between sibling history and MI (combined HR, 1.39, 95 percent CI, 1.04–1.86), but this was driven mostly but just one cohort.

In contrast, a familial history of MI or stroke seemed to increase the risk of CVD, according to the findings of all cohorts except CARLA.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 3 days ago
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Audrey Abella, 5 days ago
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Pearl Toh, 21 Sep 2020
Early and sustained treatments with simplified regimen are the key to achieving good asthma control, said experts during a presentation at the ERS 2020 Congress.
Roshini Claire Anthony, 12 Oct 2020

Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.